Finance

Lists
Q3 2026 earnings • released • EPS miss -१८.६५%
See results
MLYS:NASDAQ
Mineralys Therapeutics Inc
US$ १५.२४
-१०.३५%
(-१.७६) 1D
US$ १५.२९
+०.३३% (+०.०५०)
After hours
Closed: नोभेम्बर ५, १६:००:०२ GMT-५  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MLYS...
Open
US$ १७.६६
High
US$ १७.६६
Low
US$ १५.१५
Mkt. cap
१.३५ अरब
Avg. vol.
१६.६४ लाख
Volume
०.००
52-wk high
US$ ४७.६५
52-wk low
US$ १५.१५
EPS
-US$ ४.२४
Beta
०.८३
Shares outstanding
८.८४ करोड
No. of employees
७६
Open
US$ १७.६६
High
US$ १७.६६
Low
US$ १५.१५
Mkt. cap
१.३५ अरब
Avg. vol.
१६.६४ लाख
Volume
०.००
52-wk high
US$ ४७.६५
52-wk low
US$ १५.१५
EPS
-US$ ४.२४
Beta
०.८३
Shares outstanding
८.८४ करोड
No. of employees
७६
News stories
From web sources and news partners
About Mineralys Therapeutics Inc
CEO-
Employees७६
Founded२०१९
Headquarters-
SectorHealth Care
Industry-
Websitemineralystx.com
Analyst ratings
Based on 9 analysts giving stock ratings to MLYS in the past 3 months
Strong buy
Buy
8
Hold
1
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for MLYS in the last 3 months.
Highest
Current US$ १५.२४
US$ ५६.०० (+२६७.४५%)
Average
US$ ४४.३८ (+१९१.२१%)
Lowest
US$ १७.०० (+११.५५%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jason Gerberry
Bank of America Securities
Buy
Maintained
-
-
11/05/2026
Tara Bancroft
TD Cowen
Buy
Maintained
US$ १७.००
+११.५%
11/05/2026
Annabel Samimy
Stifel Nicolaus
Buy
Reiterated
US$ ५२.००
+२४१.२%
11/05/2026
Matthew Caufield
H.C. Wainwright
Buy
Reiterated
US$ ५६.००
+२६७.५%
11/05/2026
Unknown Analyst
UBS
Hold
Initiated
US$ २९.००
+९०.३%
10/11/2026
Alice Nettleton
UBS
Hold
Initiated
US$ २९.००
+९०.३%
10/11/2026
Seamus Fernandez
Guggenheim
Buy
Reiterated
US$ ५२.००
+२४१.२%
08/12/2026
Richard Law CFA
Goldman Sachs
Buy
Maintained
US$ ४०.००
+१६२.५%
08/12/2026
Mohit Bansal
Wells Fargo
Buy
Maintained
US$ ५५.००
+२६०.९%
08/12/2026
Unknown Analyst
Wells Fargo
Buy
Maintained
US$ ५५.००
+२६०.९%
08/12/2026
Rami Katkhuda
LifeSci Capital
Buy
Maintained
US$ ५४.००
+२५४.३%
08/12/2026
Unknown Analyst
Goldman Sachs
Buy
Reiterated
US$ ४२.००
+१७५.६%
05/07/2026
Last report
२०२६ नोभेम्बर ४
Fiscal period
Q3 2026
-US$ ०.६४ / -US$ ०.५४
-१८.६५%miss
Revenue / Est. (USD)
- / ०.००
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
२०२६ सेप्टेम्बर
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
२.४४ करोड
२.४४ करोड
२२.१४ करोड
२.२७ करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
१.३९ करोड
२.१० करोड
२.४७ करोड
३.७४ करोड
Operating expense
३.८३ करोड
४.५३ करोड
२४.६० करोड
६.०१ करोड
Total operating expenses
३.८३ करोड
४.५३ करोड
२४.६० करोड
६.०१ करोड
Operating income
-३.८३ करोड
-४.५३ करोड
-२४.६० करोड
-६.०१ करोड
Other non operating income
१.०० हजार
५.०० हजार
१३.०० हजार
५९.४७ लाख
EBT including unusual items
-३.२२ करोड
-३.९३ करोड
-२४.११ करोड
-५.७३ करोड
EBT excluding unusual items
-३.२२ करोड
-३.९३ करोड
-२४.११ करोड
-५.७३ करोड
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-३.२२ करोड
-३.९३ करोड
-२४.११ करोड
-५.७३ करोड
Net profit margin
-
-
-
-
Earnings per share
-०.४०
-०.४७
-२.८५
-०.६४
Interest and investment income
६०.४५ लाख
५९.९६ लाख
४९.५६ लाख
-
Interest expense
-
-
-
-३१.८८ लाख
Net interest expenses
६०.४५ लाख
५९.९६ लाख
४९.५६ लाख
-३१.८८ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-३.८३ करोड
-४.५३ करोड
-२४.६० करोड
-६.०१ करोड
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google एपहरू